首页 | 本学科首页   官方微博 | 高级检索  
     


Restrictive allograft syndrome after lung transplantation: new radiological insights
Authors:Adriana?Dubbeldam  author-information"  >  author-information__contact u-icon-before"  >  mailto:adriana.dubbeldam@uzleuven.be"   title="  adriana.dubbeldam@uzleuven.be"   itemprop="  email"   data-track="  click"   data-track-action="  Email author"   data-track-label="  "  >Email author  author-information__orcid u-icon-before icon--orcid u-icon-no-repeat"  >  http://orcid.org/---"   itemprop="  url"   title="  View OrcID profile"   target="  _blank"   rel="  noopener"   data-track="  click"   data-track-action="  OrcID"   data-track-label="  "  >View author&#  s OrcID profile,Caroline?Barthels,Johan?Coolen,Johny?A.?Verschakelen,Stijn?E.?Verleden,Robin?Vos,Geert?M.?Verleden,Walter?De?Wever
Affiliation:1.Department of Radiology,University Hospitals Leuven,Leuven,Belgium;2.Department of Pneumology,University Hospitals Leuven,Leuven,Belgium
Abstract:

Objectives

To describe the CT changes in patients with restrictive allograft syndrome (RAS) after lung transplantation, before and after clinical diagnosis.

Methods

This retrospective study included 22 patients with clinical diagnosis of RAS. Diagnosis was based on a combination of forced expiratory volume (FEV1) decline (≥20 %) and total lung capacity (TLC) decline (≥10 %). All available CT scans after transplantation were analyzed for the appearance and evolution of lung abnormalities.

Results

In 14 patients, non-regressing nodules and reticulations predominantly affecting the upper lobes developed an average of 13.9 months prior to the diagnosis of RAS. Median graft survival after onset of non-regressing abnormalities was 33.5 months, with most patients in follow-up (9/14). In eight patients, a sudden appearance of diffuse consolidations mainly affecting both upper and lower lobes was seen an average of 2.8 months prior to the diagnosis of RAS. Median graft survival was 6.4 months after first onset of non-regressing abnormalities, with graft loss in most patients (6/8).

Conclusions

RAS has been previously described as a homogenous group. However, our study shows two different groups of RAS-patients: one with slow progression and one with fast progression. The two groups show different onset and progression patterns of CT abnormalities.

Key points

? RAS is the newest discovered form of chronic lung allograft dysfunction (CLAD). ? RAS is not a homogenous group, as survival varies greatly between patients. ? In this study, we see two different CT onset and progression patterns. ? These two different CT patterns also correlate with a different survival rate.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号